SecBot SecBot
8-K ·Filed May 8, 2026

ARTV

Artiva Biotherapeutics, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed6mo ago SEC0001193125-26-214711
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

Expect heavy selling pressure as the market digests this massive dilutive offering. Monitor the stock for after-market trading; the offering effectively doubles the share count and signals significant cash burn. Avoid buying into weakness until the stock stabilizes post-offering.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.60
T+0 close · May 8, 2026 · via day close
Latest settled
+9.34%
T+60 · $11.59
Vs SPY
+4.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 11 $10.60entry
  2. T+1 · 6mo ago 0.00%α +0.14% · $10.60
  3. T+5 · 6mo ago −13.02%α −12.93% · $9.22
  4. T+20 · 5mo ago −31.42%α −31.11% · $7.27
  5. T+60 · 3mo ago +9.34%α +4.95% · $11.59
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Artiva Biotherapeutics priced a $300M underwritten public offering of 23.9M shares and pre-funded warrants for 2.2M shares at $11.52 per share, equating to roughly 100% dilution of existing shares. The massive capital raise signals urgent cash needs for a pre-revenue biotech and will severely dilute existing shareholders.

Key Facts

  • Offering of 23,871,526 shares and 2,170,138 pre-funded warrants for common stock
  • Price: $11.52 per share; $11.5199 per pre-funded warrant
  • Gross proceeds approximately $300 million
  • Closing expected May 11, 2026
  • Dilution of ~50% to ~100% relative to pre-offering share count

Financial Impact

Approximately $300 million gross proceeds, representing ~50-100% dilution of existing equity based on pre-offering market cap of ~$309 million

dilutionsharesOutstanding

Risk Factors

  • Extreme dilution to existing shareholders
  • Potential for further capital raises if cash burn continues
  • Downward pressure on stock price as new shares enter the market

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-214711
Document: d20969dex41.htm0001193125-26-214711
Document: d20969d8k.htm0001193125-26-214711
Document: d20969dex51.htm0001193125-26-214711
Document: 0001193125-26-214711-index-headers.html0001193125-26-214711
Document: 0001193125-26-214711-index.html0001193125-26-214711
Document: 0001193125-26-214711.txt0001193125-26-214711

Track record

33 reports on ARTV

Performance horizon

10 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 7h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026